IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announces that the U.S. Food and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 27, 2023 Category: Pharmaceuticals Source Type: clinical trials
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
Conditions: Esophageal Squamous Carcinoma; HER-2 Protein Overexpression Intervention: Drug: RC48+PD-1+platinum-based Sponsor: Changhai Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
Conditions: Esophageal Squamous Carcinoma; HER-2 Protein Overexpression Interventions: Drug: RC48+PD-1+platinum-based Sponsors: Changhai Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
22 September 2023 -- Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic HER2-negative Breast Cancer
Condition: Locally Advanced or Recurrent Metastatic HER-2 Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: SI-B003 Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Condition: Gastroesophageal Adenocarcinoma Interventions: Drug: Paclitaxel; Drug: Ramucirumab; Drug: Zanidatamab Sponsors: Canadian Cancer Trials Group; Jazz Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases
Conditions: Breast Cancer; Metastatic Breast Cancer Intervention: Drug: Trastuzumab-Deruxtecan (T-DXd) Sponsors: MedSIR; Daiichi Sankyo, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
